NCT06904547View on ClinicalTrials.gov

Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

April 20, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

December 31, 2030

Conditions
ALK-Positive NSCLC
Interventions
OTHER

No intervention administered

No intervention administered

OTHER

Non Interventional Study

Non Interventional Study

All Listed Sponsors
lead

Shanghai Chest Hospital

OTHER

NCT06904547 - Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC | Biotech Hunter | Biotech Hunter